Skip to Content
Merck
CN

PLA0184

Rabbit anti-PARP1 Antibody, Affinity Purified

Powered by Bethyl Laboratories, Inc.

Synonym(s):

ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase), ADP-ribosyltransferase NAD(+), ADP-ribosyltransferase diphtheria toxin-like 1, ADPRT, ADPRT 1, ADPRT1, ARTD1, NAD(+) ADP-ribosyltransferase 1, PARP, PARP-1, PPOL, member 1, pADPRT-1, poly (ADP-ribose) polymerase 1, poly (ADP-ribose) polymerase family, poly(ADP-ribose) polymerase, poly(ADP-ribose) synthetase, poly(ADP-ribosyl)transferase, poly[ADP-ribose] synthase 1

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
WB
Citations:
32
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


biological source

rabbit

Quality Level

conjugate

unconjugated

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

clone

polyclonal

species reactivity

human

technique(s)

western blot: 1:2,000-1:10,000

accession no.

NP_001609.1

UniProt accession no.

shipped in

wet ice

storage temp.

2-8°C

target post-translational modification

unmodified

Gene Information

rabbit ... PARP1(142)

Immunogen

The epitope recognized by PLA0184 maps to a region between residue 1 and 50 of human poly (ADP-ribose) polymerase family, member 1 using the numbering given in entry NP_001609.1 (GeneID 142).

Physical form

Tris-buffered Saline containing 0.1% BSA containing 0.09% Sodium Azide

Other Notes

PARP1 (Poly-ADP-ribose polymerase 1) is a member of PARP family of enzymes that transfer the ADP-D-ribosyl group of NAD(+) to an acceptor carboxyl group on proteins. PARP1 catalyzes the poly-ADP-ribosylation of histone and non-histone proteins in response to DNA damage. The over-activation of PARP-1 in response to DNA damage has been shown to promote cell and tissue injury. This observation has initiated research into the therapeutic potential of PARP1 inhibitors in the treatment of cancer, cardiovascular disease, and brain injury.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

Try our Product Selector Tool to narrow your options


Storage Class

12 - Non Combustible Liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

常规特殊物品
低风险生物材料

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Shaohua Chen et al.
Cancer letters, 348(1-2), 20-28 (2014-02-19)
In this study, we explored the antitumor activities of the PARP inhibitor AZD2281 (Olaparib) and the pan-Bcl-2 inhibitor GX15-070 (Obatoclax) in six pancreatic cancer cell lines. While both agents were able to cause growth arrest and limited apoptosis, the combination
Jessica Svedlund et al.
Endocrine-related cancer, 21(2), 231-239 (2013-12-03)
Primary hyperparathyroidism (pHPT) resulting from parathyroid tumors is a common endocrine disorder with incompletely understood etiology. In renal failure, secondary hyperparathyroidism (sHPT) occurs with multiple tumor development as a result of calcium and vitamin D regulatory disturbance. The aim of
François Lamoureux et al.
European urology, 66(1), 145-155 (2014-01-15)
Although prostate cancer responds initially to androgen ablation therapies, progression to castration-resistant prostate cancer (CRPC) frequently occurs. Heat shock protein (Hsp) 90 inhibition is a rational therapeutic strategy for CRPC that targets key proteins such as androgen receptor (AR) and



Global Trade Item Number

SKUGTIN
PLA0184-100UL04061837722912